Thermo Fisher Scientific Durvalumab Monoclonal Antibody (15D6)
Durvalumab(임핀지) 항암제에 대한 마우스 단클론 항체(15D6). ELISA 및 Blocking Assay에 사용 가능. 인간 PD-L1과 PD-1 상호작용 차단 연구용. 동결건조 형태, Protein A 정제, -20°C 이하 보관.
- 판매단위
- pk
카탈로그
1개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다Thermo Fisher Scientific · Thermo Fisher Scientific Durvalumab Monoclonal Antibody (15D6)
Thermo Fisher Scientific Durvalumab Monoclonal Antibody (15D6)
Applications and Tested Dilution
| Application | Tested Dilution |
|---|---|
| ELISA (ELISA) | 0.01–0.1 µg/mL |
| Blocking Assay (BLOCK) | 5–30 µg/mL |
Product Specifications
| 항목 | 내용 |
|---|---|
| Species Reactivity | Human |
| Host/Isotype | Mouse / IgG2a, kappa |
| Class | Monoclonal |
| Type | Antibody |
| Clone | 15D6 |
| Immunogen | Durvalumab |
| Conjugate | Unconjugated |
| Form | Lyophilized |
| Purification | Protein A |
| Storage Buffer | PBS, pH 7.4 |
| Contains | 0.02% sodium azide |
| Storage Conditions | -20°C or -80°C if preferred |
| Shipping Conditions | Ambient (domestic); Wet ice (international) |
Product Specific Information
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Durvalumab, trade name Imfinzi, is an FDA-approved anti-cancer drug known as a checkpoint inhibitor developed by Medimmune/AstraZeneca.
Durvalumab is a human IgG1 kappa monoclonal antibody that blocks the interaction between programmed cell death ligand 1 (PD-L1) and PD-1 (CD279).
Anti-Durvalumab Antibody (15D6), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Durvalumab.
Target Information
Durvalumab (Imfinzi) is a checkpoint inhibitor drug developed by Medimmune/AstraZeneca.
It is a human IgG1 kappa monoclonal antibody that blocks PD-L1 and PD-1 (CD279) interaction.
Usage Note
For Research Use Only.
Not for use in diagnostic procedures.
Not for resale without express authorization.
제품 이미지
Thermo Fisher Scientific 상품 둘러보기
전체보기
문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.